Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMDs) for early cancer ...
Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results